Products for Research Use Only

Nor-NOHA (monoacetate)

CAT: 0804-HY-112885B-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112885B-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism[1].
CAS Number
2250019-93-1
Product Name Alternative
Nω-Hydroxy-nor-L-arginine (monoacetate)
UNSPSC
12352211
Target
Arginase
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/nor-noha-monoacetate.html
Purity
99.96
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)
Smiles
N[C@H](C(O)=O)CCNC(NO)=N.O=C(C)O
Molecular Formula
C7H16N4O5
Molecular Weight
236.23
References & Citations
[1]Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13 (10) :e0205254.|[2]Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85 (1) :147-54.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Citation 01
Cell. 2025 Dec 11;188 (25) :7291-7308.e23.|FASEB J. 2025 Sep 30;39 (18) :e71057.|Front Cell Dev Biol. 2021 Dec 23;9:741911.|Clin Immunol. 2024 Sep 3:110355.